A Duke University team says a one-time gene therapy, delivered by catheter straight into damaged heart muscle, helped weakened hearts regain strength and calm their electrical chaos in early laboratory and animal tests. In engineered human heart tissue and later in macaque monkeys, treated hearts showed stronger pumping and fewer dangerous rhythm problems. If those results hold up in people, the approach could offer a less invasive option than surgery and a fresh way to stop patients from sliding from heart attack into full-blown heart failure.
As reported by the Duke Pratt School of Engineering, the work, which appears in Circulation Research, found that a single injection largely restored the monkeys' ability to pump blood and sharply cut arrhythmias within weeks. Study authors, including postdoctoral researcher Tianyu Wu and Professor Nenad Bursac, describe a two-pronged tactic that boosts how forcefully heart cells contract while also improving how electrical signals spread through injured tissue. The Duke engineers note that they did not see adverse effects during the monitoring period and say they are already moving into pig studies as the next step toward real-world use.
How the therapy works
The experimental treatment relies on a compact, engineered bacterial voltage-gated sodium channel known as BacNa_v. The construct is small enough to fit into standard viral delivery vectors, which lets it crank up sodium current in damaged cardiomyocytes and make them easier to activate. In the paper and related releases, the researchers report that BacNa_v expression increased calcium transients and contractile force and smoothed conduction across injured regions, which lowered arrhythmia risk, according to EurekAlert. Because the gene package is compact, it can ride inside commonly used vectors and, in these tests, was threaded in by catheter directly into the infarct zone instead of through open-heart surgery.
Why it matters
Cardiovascular disease is still the planet's top killer, responsible for roughly 18 million deaths each year. Heart disease remains the leading cause of death in the United States as well. Data from the World Health Organization and U.S. mortality reports show the scope of the crisis, with the CDC listing heart disease among the chief causes of death nationally and reporting roughly 680,000 to 695,000 such deaths in recent years. A treatment that preserves or restores contractile muscle after a heart attack could, at least on paper, slow or prevent the long march toward heart failure for millions of survivors.
The Duke group is quick to point out that success in engineered tissues and animal models is promising but not proof that the same benefits will appear in people. As reported by Duke Today, the lab says the genes used in the monkey study were not detected outside the treated heart region and no short-term harms turned up during follow-up, but they also stress that longer observation and independent testing are essential, along with careful dose studies. Local coverage from WISH-TV notes that the upcoming pig studies, along with regulatory review, will decide whether this one-shot heart fix is ready to be tried in an early human clinical trial.
.jpg){kind=link}